Taxpayer Funding

  • |

    NVIDIA Got the Chip, Taxpayers Got the Receipt

    ByPhil McCracken

    I opened the taxpayer invoice and found the usual public-private magic trick: grants, university science, and open research absorb the early risk, then NVIDIA turns the broader foundation into products while the public contribution vanishes from the paperwork. To be clear, that does not mean NVIDIA did nothing or that taxpayers legally own the company. It means the money trail deserves more than a ceremonial thank-you card.

    At the public invoice desk, the down payment is stamped complimentary, while the private payoff arrives with enough zeros to require its own zip code. Fair taxes, public reinvestment, or public-interest conditions are not radical demands when shared science helps make extraordinary fortunes possible. Follow the invoice and ask the plain question: if the public helped build the future, why is its return always listed as “pending”?

  • |

    Public Science, Private Checkout

    ByHarlan Quill

    I keep a library card and a calculator nearby for moments like this: taxpayers help fund NIH and university research, then meet the finished medicine at the pharmacy counter priced like a used county courthouse. Not every treatment follows that exact route, and public research can benefit everyone. But when public money absorbs much of the early risk while private companies control the patent and the price, the arrangement deserves more than a ceremonial ribbon cutting.

    The institutional math is remarkably tidy. Public laboratories supply knowledge, universities supply talent, investors celebrate the next big product, and patients receive the portion marked “due now.” That is not necessarily unlawful; it is simply a system with impressive machinery for privatizing the upside and outsourcing the bill. A sensible public investment should purchase public leverage, affordable access, or both. Otherwise taxpayers sponsored discovery, investors collected the dividend, and patients were assigned to crowd-fund the receipt.

  • |

    The Public Helped Prove Remdesivir—Then Got the Invoice

    ByPhil McCracken

    I follow the invoice, and Remdesivir leads straight to the strangest line item in pandemic economics: public support helping carry the research risk while Gilead’s approximately $3,120 list-price headline arrives like the taxpayer has never met the taxpayer. That figure was not necessarily every patient’s final bill, and public funding did not pay for every step of the work. But the fairness problem remains plain: when public money helps steady the ladder, private billing should not act like it built the building alone.

    America gets cast as both venture capitalist and customer—asked to help finance the uncertain part, then sent shopping at the counter once the emergency treatment is ready. The money trail wore cologne, but the receipt still smells like a double charge: first as research backer, then as buyer. If public science helps make a medical breakthrough possible, why does the public receive so little leverage over the price and so much responsibility for paying it?

  • |

    Wall Street’s New Favorite Dance: The Medicare Money Shuffle

    ByJustin Jest

    Picture the dance floor at a swanky Wall Street gala, where every beat syncs perfectly with Medicare’s cascading cash flow. It’s not a fundraiser—it’s a celebration, where taxpayer dollars pirouette elegantly into the pockets of America’s financial titans, who are somehow always in step with ‘limited competition’ and ‘ever-growing margins.’

    Think of it as a public funds tango; a dance we never learned, yet we’re forever financing. High prices are the new sheet music—every note drenched in champagne and caviar, while the taxpayers sit in the bleachers, wondering if they missed the invite or just funded it. Welcome to the ultimate societal shoulder shrug, where public funding becomes Wall Street’s limitless conga line!

End of content

End of content